Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorIrvine-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.creatorSharma, Ajay N.-
Autor(es): dc.creatorMichelle, Lauren-
Autor(es): dc.creatorJuhasz, Margit-
Autor(es): dc.creatorMuller Ramos, Paulo [UNESP]-
Autor(es): dc.creatorAtanaskova Mesinkovska, Natasha-
Data de aceite: dc.date.accessioned2022-02-22T00:26:03Z-
Data de disponibilização: dc.date.available2022-02-22T00:26:03Z-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-08-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1111/ijd.14933-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/198961-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/198961-
Descrição: dc.descriptionBackground: Topical minoxidil has been used for almost 40 years to treat alopecia. There is growing evidence supporting off-label use of low-dose oral minoxidil. Objective: To conduct a systematic review evaluating the use of oral minoxidil for all types of alopecia. Methods: A primary literature search was conducted using PubMed in May 2019, utilizing the search term “oral minoxidil AND (hair loss OR alopecia OR baldness)”. Reviews, non-English studies, and articles concerning only topical minoxidil were excluded. Results: Ten articles were included for review comprising a total 19,218 patients (215 women and 19,003 men). Oral minoxidil dose ranged from 0.25 to 5 mg daily to twice daily. The strongest evidence existed for androgenetic alopecia and alopecia areata (AA), with 61–100% and 18–82.4% of patients demonstrating objective clinical improvement. Successful treatment of female pattern hair loss, chronic telogen effluvium, monilethrix, and permanent chemotherapy-induced alopecia was also reported. The most common adverse effects with oral minoxidil included hypertrichosis and postural hypotension. Conclusion: Oral minoxidil is a safe and successful treatment of androgenic alopecia and AA. In addition to its therapeutic benefits, practical advantages over topical minoxidil stem from improved patient compliance.-
Descrição: dc.descriptionDepartment of Dermatology University of California Irvine-
Descrição: dc.descriptionSão Paulo State University – UNESP-
Descrição: dc.descriptionSão Paulo State University – UNESP-
Formato: dc.format1013-1019-
Idioma: dc.languageen-
Relação: dc.relationInternational Journal of Dermatology-
???dc.source???: dc.sourceScopus-
Título: dc.titleLow-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.